B · Normal
[Animal experiments show: CRISPR therapy achieves three-year lipid control with one infusion] On November 17, scientists from Verve Therapeutics, a subsidiary of Eli Lilly and Company, published a study in the new issue of Nature magazine saying that the CRISPR base editing therapy they developed achieved a single infusion in cynomolgus monkeys and sustained lipid control for three years, providing a new way for patients to get rid of daily medication.
Global market intelligence 🕐 2026-11-17 06:59

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet